DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
Rhea-AI Summary
Mainz Biomed (NASDAQ:MYNZ) announced that its DNA-based colorectal cancer home test ColoAlert was added to DoctorBox’s digital health portfolio on Dec 2, 2025. The move integrates Mainz Biomed’s diagnostics with DoctorBox’s platform and routes laboratory analysis to the European Oncology Lab led by Dr. Annette Buhlmann in St. Ingbert, Germany.
DoctorBox reports >1 million registered users and >10 million test results, and the partnership aims to expand at‑home access to DNA colorectal screening in Germany, where ~60,000 new colorectal cancer cases are diagnosed annually.
Positive
- ColoAlert added to DoctorBox portfolio, enabling wider distribution
- Access to >1 million DoctorBox users and >10 million historical test results
- Laboratory analysis assigned to European Oncology Lab led by Dr. Annette Buhlmann
Negative
- None.
News Market Reaction
On the day this news was published, MYNZ gained 2.65%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.2% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $264K to the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ADVB +6.37%, CHEK +2.55%, XWEL +0.65%, BIAF +0.61%, while ISPC -1.56%, suggesting today’s action in MYNZ is more stock-specific than sector-wide.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Digital partnership | Positive | +2.6% | ColoAlert added to DoctorBox, expanding at-home colorectal screening access in Germany. |
| Nov 18 | Geographic expansion | Positive | -4.8% | MOU with OncoVanguard8 to introduce ColoAlert across initial South American markets. |
| Nov 12 | Trade show presence | Positive | +4.6% | Showcasing ColoAlert and early-stage diagnostics at MEDICA 2025 in Düsseldorf. |
| Nov 10 | Medical conference | Positive | +0.8% | Participation at GARPS meeting to present ColoAlert and discuss collaborations. |
| Oct 15 | Investor conference | Positive | -3.9% | Attendance at 2025 Maxim Growth Summit for meetings with institutional investors. |
Commercial and conference news has generally been positive, but price reactions have been mixed, with both gains and pullbacks on seemingly constructive updates.
Over the last few months, Mainz Biomed focused on expanding access to its ColoAlert colorectal cancer test and investor visibility. On Oct 22–23, 2025, it attended the Maxim Growth Summit, followed by German gastroenterology and MEDICA 2025 conference participation in mid-November. A Nov 18, 2025 MOU targeted South American markets, and on Dec 2, 2025 ColoAlert was added to DoctorBox’s platform in Germany. Together these events underline a strategy centered on partnerships, geographic expansion, and clinical engagement.
Market Pulse Summary
This announcement highlights a commercial expansion milestone: ColoAlert’s integration into DoctorBox’s digital platform, which reports over 1 million users and over 10 million test results. It reinforces Mainz Biomed’s focus on at-home, DNA-based colorectal cancer screening in a German market with around 60,000 new cases annually. In context of recent conference participation and geographic expansion plans, investors may watch future updates on test uptake, reimbursement dynamics, and further partnerships.
Key Terms
dna-based colorectal cancer screening medical
dna diagnostics medical
rna-based tests medical
digital healthcare platform technical
AI-generated analysis. Not financial advice.
DNA-based Colorectal Cancer Screening as a Home Test
BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed’s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.
Colorectal cancer is one of the most common yet preventable cancers worldwide. In Germany alone, around 60,000 new cases are diagnosed each year — a clear indicator of the need for highly effective early detection measures. By integrating Mainz Biomed’s advanced DNA diagnostics into DoctorBox’s digital healthcare platform, this collaboration establishes a highly innovative model of care that can significantly expand access to ColoAlert.
“With DoctorBox, we are gaining a strong partner that enables us to offer ColoAlert exactly where prevention can take place today — at home,” said Guido Baechler, CEO of Mainz Biomed. “Together, we are lowering barriers to colorectal cancer screening and providing easy access to DNA-based early detection.”
“ColoAlert fits perfectly into our portfolio of next-generation DNA- and RNA-based tests. Thus, innovative colorectal cancer screening becomes another cornerstone of our digital preventive healthcare platform,” said Julian Maar, CEO of DoctorBox.
The DoctorBox app brings together modern preventive healthcare services on a single platform: with over one million registered users and more than ten million test results transmitted, DoctorBox ranks among Europe’s leading digital prevention solutions. The offering includes guideline-based preventive-care reminders – personalized by age, sex, and risk profile. Additional services include at-home tests and locally accessible diagnostics, for example for early detection of colorectal, cervical, and prostate cancer (self-pay or reimbursed). Measures for sexual health, allergies, as well as innovative analyses, digital evaluation and support – including the delivery of findings, recommendations for action, and video consultations directly within the app – are also part of the DoctorBox offering.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About DoctorBox
DoctorBox is setting the new standard for prevention in Europe — made in Germany.
As one of Germany’s leading digital solutions for smart preventive healthcare, DoctorBox empowers more than one million users in Germany and other European countries to manage their health prevention easily, digitally, and independently. Whether through reminders, at-home tests, or local diagnostics, DoctorBox makes preventive healthcare accessible and part of everyday life.
To learn more, visit doctorbox.de.
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.
To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
FAQ
What did Mainz Biomed (MYNZ) announce on December 2, 2025?
How will the DoctorBox partnership affect ColoAlert distribution for MYNZ?
Who will perform laboratory analysis for ColoAlert under the DoctorBox collaboration?
What scale of colorectal cancer incidence did Mainz Biomed cite for Germany?
Does DoctorBox already have an established user base relevant to MYNZ shareholders?
